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Epidemiological studies have shown that genetic factors contribute to the etiology of the common and serious
pregnancy-specific disorder pre-eclampsia (PE)/eclampsia (E). Candidate-gene studies have provided evidence (albeit
controversial) of linkage to several genes, including angiotensinogen on 1q42-43 and eNOS on 7q36. A recent
medium-density genome scan in Icelandic families identified significant linkage to D2S286 (at 94.05 cM) on chro-
mosome 2p12 and suggestive linkage to D2S321 (at 157.5 cM) on chromosome 2q23. In the present article, the
authors report the results of a medium-density genome scan in 34 families, representing 121 affected women, from
Australia and New Zealand. Multipoint nonparametric linkage analysis, using the GENEHUNTER-PLUS program,
showed suggestive evidence of linkage to chromosome 2 ( ), at 144.7 cM, between D2S112 andD2S151,LODp 2.58
and to chromosome 11q23-24, between D11S925 and D11S4151 ( at 121.3 cM). Given the limitedLODp 2.02
precision of estimates of the map location of disease-predisposing loci for complex traits, the present finding on
chromosome 2 is consistent with the finding from the Icelandic study, and it may represent evidence of the same
locus segregating in the population from Australia and New Zealand. The authors propose that the PE/E-linked
locus on chromosome 2p should be designated the “PREG1” (pre-eclampsia, eclampsia gene 1) locus.
Pre-eclampsia (PE [MIM 189800]) is a complex and se-
rious disorder of human pregnancy, with a worldwide
incidence of 2%–5%. It is characterized by the devel-
opment, in the latter half of pregnancy, of new-onset
hypertension that resolves postpartum (Roberts and
Redman 1993; Witlin and Sibai 1997; Davey and Mac-
Gillivray 1988). In its severe form the disorder produces
significant proteinuria, edema, and multiorgan dysfunc-
tion. There is no reliable predictive test, nor is there an
effective medical therapy to treat this serious condition.
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The most worrisome complication of PE is its unpre-
dictable progression to eclampsia (E), a convulsive con-
dition that is life threatening for both mother and infant.
Although the full etiology and pathogenesis of PE/E
are unknown, it is accepted that the placenta is involved
in a fundamental manner. The evidence to date suggests
that abnormal interaction between maternal and fetal
tissues during placentation may be the initiating factor
in the complex chain of events that constitute the syn-
drome of PE/E. In a normotensive pregnancy, cytotro-
phoblasts invade the spiral arterioles, replacing the en-
dothelium and removing the muscular covering of the
arterioles (Robertson et al. 1967; Zhou et al. 1997). The
arterioles therefore dilate, and the decidual-trophoblast
blood flow is increased. These events take place at 15–18
wk of pregnancy. In PE/E pregnancies the invasion of
the spiral arterioles by the cytotrophoblasts is limited.
They remain small in diameter and retain their muscular
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covering, with a consequent relative restriction of ma-
ternal blood flow to the placenta (Brosens et al. 1972;
Gerretsen et al. 1981; Khong et al. 1986; Redman 1991;
Zhou et al. 1997). This histopathological defect in PE/E
pregnancies precedes the onset of clinical symptoms. A
widely proposed hypothesis attempts to link the defect
to the eventual onset of symptoms by postulating that
the reduced maternal placental blood flow leads to pla-
cental hypoxia, with consequent release of toxic factors
from the placenta into the maternal circulation, which
causes a generalized dysfunction of maternal vascular
endothelial cells. In turn, this dysfunction perturbs the
balance of endothelial cell–derived vasoactive autacoids
(e.g., prostacyclin, nitric oxide, and endothelin) and
thereby leads to the generalized vasospasm, diminished
tissue perfusion, and hypoxia of organs (e.g., the brain,
kidneys and liver) that are characteristic of PE/E (Red-
man 1991; Roberts and Redman 1993; Arbogast et al.
1994; Lim et al. 1997; Taylor 1997; Higgins and Bren-
necke 1998; Page et al. 2000).
It is widely accepted that genetic factors play a major
role in susceptibility to PE/E (Cooper et al. 1993; Pipkin
1999; Ros et al. 2000), and several models of inheritance
have been proposed (Cooper and Liston 1979; Arn-
grı´msson et al. 1995; Graves 1998). Although none of
these has been proved, it is likely that paternal genes
acting through the fetus contribute in some way to the
mother’s risk (Thornton and Onwude 1991; Lie et al.
1998; Ros et al. 2000). PE/E, like many common human
diseases (e.g., heart disease, diabetes, cancer, and hy-
pertension) is a multifactorial trait that is probably in-
fluenced by combinations of genetic and nongenetic risk
factors, complicating the process of identifying them (see
Terwilliger and Go¨ring 2000). There have been con-
certed efforts to identify the maternal risk genes, mostly
focused on candidate genes (Cooper et al. 1993; Roberts
and Cooper 2000), but results to date have been am-
biguous at best. Genome-scan studies have reported find-
ings on chromosomes 4q (Harrison et al. 1997) and
2p13 (Arngrı´msson et al. 1999), for the latter of which
we find strong confirmatory evidence in our current ge-
nome scan, as indicated in the present report.
We have performed a genome scan to identify mater-
nal genes whose genotypes may influence the risk of
developing PE; 366 individuals from 26 Australian and
8 New Zealand families were genotyped at 400 micro-
satellite markers, with fluorescence-labeled primer pairs
from the ABI PRISM Human Linkage Mapping Set, ver-
sion 2 (PE Biosystems). The families were recruited over
a 15-year period (1984–99), through the Royal Women’s
Hospital and the Monash Medical Centre in Melbourne
and via print and electronic media advertisements in
Sydney and through the National Women’s Hospital,
Auckland. Subsets of the 26 Australian families have
been used in earlier studies (Wilton et al. 1990, 1991,
1995; Humphrey et al. 1995; Guo et al. 1997, 1999;
Harrison et al. 1997; Lade et al. 1999). The 34 families
included 13 women with E, 74 women with severe PE,
34 women who had hypertensive first pregnancies with-
out proteinuria (mild PE), and 71 women who had
normotensive first pregnancies. Diagnosis was based on
clinical assessment, using the criteria of the Australasian
Society for the Study of Hypertension in Pregnancy
(Brown et al. 1993), which are very similar to those used
in the recently reported genome scan from Iceland (Arn-
grı´msson et al. 1999). Pregnant women were considered
to have severe PE if they had either (1) an increase of
25 mm Hg above baseline systolic blood pressure and/
or an increase of 15 mm Hg above baseline diastolic
blood pressure or (2) a persistent systolic blood pressure
of 140 mm Hg and/or a diastolic blood pressure of
90 mm Hg. These levels had to occur on at least two
occasions 6 h apart. The level of proteinuria had to
be 10.3 g/liter in a 24-h specimen, or the dipstick pro-
teinuria score had to be 2 in a random urine collec-
tion. Women who met these criteria and who had ex-
perienced either convulsions or unconsciousness in the
perinatal period were classified as having had E. Because
PE/E is typically a disease of first pregnancies (Chesley
et al. 1968; Fisher et al. 1981), only those women with
the above-mentioned features in their first and not in
their subsequent pregnancies were included in this study.
Women with preexisting hypertension or other medical
diseases known to predispose them to PE were excluded.
Approval for this study was obtained from the ethics-
review committees of all relevant institutions, and in-
formed written consent was obtained from family mem-
bers before peripheral blood samples were taken.
The genotyping for chromosomes 2, 5, 6, 15, 16, and
19–22 was performed by the Australian Genome Re-
search Facility. The remaining autosomes and chromo-
some X were genotyped by the authors. For genotyping,
genomic DNA was extracted from the blood samples,
with a commercial kit (Blood and Cell Culture DNA
Midi Kit; Qiagen). PCR reactions (10 ml) were set up in
384-well polypropylene microplates (MJ Research), with
a HYDRA-96 micropipetting robot (Robbins Scientific),
and contained 34 ng of genomic DNA, 0.33 mM of each
primer, 250 mM of each deoxynucleotide and 2.5 mM
MgCl2, together with 0.4 U of AmpliTaq Gold DNA
polymerase and 1#GeneAmp PCR Buffer II (both from
PE Biosystems). The reactions were carried out using
FTS-960 thermal sequencers modified to accommo-
date 384-well plates (Corbett Research) and were pro-
grammed to deliver the following cycling profile: 1 cycle
at 95C for 10 min, to activate the DNA polymerase;
10 cycles of denaturation at 94C for 15 s, annealing at
55C for 15 s, and extension at 72C for 30 s; followed
by 20 additional cycles that were identical, apart from
a reduced denaturation temperature of 89C. The re-
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Figure 1 Multipoint nonparametric linkage analysis using the Sall scoring function in the GENEHUNTER-PLUS modification of the
GENEHUNTER package. The GENEHUNTER-PLUS LOD scores on the Y axis are plotted against the genetic distance, in cM, on the X axis.
actions were then finished with a final extension step at
72C for 10 min. The PCR products were pooled using
the HYDRA-96, and, after the addition of fluorescence-
labeled internal size standards, were separated by elec-
trophoresis and were automatically detected on an ABI
PRISM 377 DNA sequencer equipped with GENESCAN
software, version 3.1 (PE Biosystems). The subsequent
assignment of genotypes was performed using GENO-
TYPER software, version 2.5 (PE Biosystems).
Linkage analysis was performed using the GENE-
HUNTER-PLUS package (Kruglyak et al. 1996; Kong
and Cox 1997), with the PEDMANAGER program, ver-
sion 0.9, to test for Mendelian inconsistencies. PED-
MANAGER was also used to calculate the allele fre-
quencies for each marker locus, by use of the genotypes
of the founder individuals from the 34 families with
PE/E and the genotypes of 50 additional unrelated Aus-
tralian individuals. The markers were assumed to be
positioned as indicated in the Sex-Averaged CHLC/ABI
Prism Reference Maps, version 2.0. Two diagnostic
schemes were used in the analysis—a strict diagnostic
model, in which women with E and women with severe
PE were classified as affected, and a general diagnostic
model, in which women with mild PE were also classified
as affected. An affecteds-only strategy was used, in
which we considered all men and women who had not
reproduced to be phenotypically unknown. This was
identical to the analysis performed by the Icelandic
group in their genome scan (Arngrı´msson et al. 1999).
The resulting LOD scores based on the Sall scoring func-
tion are presented in figure 1 for both the strict diag-
nostic model and the general diagnostic model. When
the general classification criteria were used, the maxi-
mum multipoint LOD score in the present study was
observed on chromosome 2q, between D2S112 and
D2S151 (LOD p 2.58 at 144.7 cM), which is not far
from the location where Arngrı´msson et al. (1999) re-
ported a LOD score (with the same statistical analysis)
of 4.7 in their Icelandic study, also based on their general
diagnostic model. (In their initial genome scan, with a
density similar to that in our scan, the maximum LOD
score was 3.14.) The peak due to this linkage finding
extended over a very wide region, with significant (P !
) markers over an 85-cM region, adding support to.05
the idea that this may be a true-positive result (see Ter-
williger et al. 1997). Furthermore, although the peaks
do not occur at exactly the same position on the chro-
mosome, the precision of genome scans for complex
traits is poor, and the estimated map locations of this
locus are sufficiently close that they are consistent with
a single risk locus in both studies, as shown in the large
simulation study by Hovatta et al. (1998). Furthermore,
as shown in figure 1, the peak for chromosome 2 rises
far above the background signals on the other chro-
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mosomes, at least under the general diagnostic model,
for which the next-highest LOD score over the whole
genome was 1 LOD unit smaller. Under the strict di-
agnostic category, the sample size was notably smaller,
and the number of regions with LOD scores approaching
2 was much larger than that under the general diagnostic
model. This is consistent with the expectation that a
higher false-positive rate would be found when a much
smaller data set is studied by linkage analysis. The best
finding under the strict diagnostic model was on chro-
mosome 11, but this does not stand out much above the
background noise. Although the LOD score on chro-
mosome 2 is somewhat lower under the strict diagnostic
model, chromosome 2 is still the second-most-significant
region in the genome scan, and the finding is consistent
with the hypothesis that a locus that influences PE/E,
irrespective of severity, may be found in the chromosome
2 region. It is noteworthy that the shape of the multi-
point LOD-score curve in our study is also similar to
that of the study by Arngrı´msson et al. (1999), with a
broad region identified in the initial scan and with minor
peaks in similar locations. We conclude that it is likely
that we and Arngrı´msson et al. (1999) have detected the
same locus on chromosome 2, and therefore we propose
that it should be designated the PREG1 (pre-eclampsia/
eclampsia gene 1) locus.
In earlier linkage studies performed using subsets of
the families used in the present study, evidence suggestive
of linkage was found for regions on chromosomes 4q
(Harrison et al. 1997) and 7q36 (Guo et al. 1999). In
the present study, under the severe classification criteria,
nominal evidence of linkage, with multipoint P values
!.05, was observed in the same region of chromosome
4q ( at 217.3 cM), but there was no evi-LODp 1.24
dence of linkage to 7q. In this context, it should be noted
that the 7q36 marker for which suggestive evidence of
linkage was previously found (D7S1805) was not geno-
typed as part of the scan described in the present report.
It is also noteworthy that, although Arngrı´msson et al.
(1999) found suggestive evidence of linkage to 7q36 in
50 families from Scotland and Iceland, they found no
evidence for linkage to this (or any other reported can-
didate region) in their subsequent genome scan in 134
Icelandic families (Arngrı´msson et al. 1999).
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